When it comes to dividend investing, there are two basic paths you can take. If you can't decide which dividend investing ...

Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder.

Cerevel Therapeutics (Cerevel), a subsidiary of AbbVie Inc, is a clinical-stage biopharmaceutical ... and darigabat targets epilepsy and panic disorder; tavapadon for both early and late-stage ...

Earlier this month, the company announced positive results for tavapadon, which met both primary ... Not every drug that is in AbbVie's pipeline is going to be a success. But this is still a ...

Earlier this month, the company announced positive results for tavapadon, which met both primary and secondary ... Not every drug that is in AbbVie's pipeline is going to be a success. But this is ...

On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial, evaluating tavapadon as a flexible-dose (5mg to 15mg, once daily) monotherapy in early ...

KOLs have expressed positive sentiments of tavapadon. Credit: Owlie Productions via Shutterstock. On 9 December 2024, AbbVie announced positive topline results from its pivotal Phase III TEMPO-2 trial ...

Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced positive topline results from its pivotal Phase 3 TEMPO-2 trial evaluating investigational tavapadon as a flexible-dose monotherapy ...

AbbVie offers a compelling investment opportunity ... in schizophrenia and novel neuroscience therapies such as tavapadon for Parkinson’s diseases. ABBV’s neuroscience capabilities are ...

AbbVie presently has an excellent rank, in the top 25% of the coverage universe, which suggests it is among the top most "interesting" ideas that merit further research by investors. But making ...

AbbVie has shared promising top-line results from a phase 3 study of its investigational Parkinson’s disease (PD) candidate tavapadon in adults and said it is “on track” to submit a new drug ...